Complication of Transplanted Lung Clinical Trial
Official title:
Assessment of Cough Reflex in Lung Transplant Recipients
The purpose of this study is to evaluate the presence of cough reflex in the transplanted lung of patients who have had either a single or double lung transplant or heart-lung transplant at University of Texas Medical Branch. At the 1 year post transplant bronchoscopy, the presence of the cough reflex will be assessed by placing 3 to 5 ml of 5% dextrose and placement of the bronchial biopsy forceps on the airway mucosa. Three to four separate areas of the transplanted airways will be assessed. The cough reflex will be assessed by recording the surface electrical activity by placing external electrodes to monitor the movement of abdominal muscles during a cough. The data will be recorded and compared with recordings from coughs recorded using the surface electrical activity of a cough generated by non-transplant patients.
Bronchoscopy Stable, lung transplant recipients undergoing surveillance bronchoscopy will be
enrolled. We will exclude subjects with new or persistent cough, hypoxemia, new radiographic
infiltrates, or hemodynamic instability.
Before bronchoscopy, patients will receive diazepam while codeine and atropine will be
withheld. Upper airway anesthesia was performed using cotton swabs soaked with 4 % lidocaine
applied on the oropharyngeal mucosa and gradually placed posteriorly with the aid of curved
foreceps to anesthetize the supraglottic region. A trained individual will perform topical
upper airway anesthesia over 15 minutes and adequate anesthesia will be determined once
subjects fail to cough during foreceps application to the supraglottic region. Conscious
sedation will be administered using intravenous midazolam while vital signs are monitored.
Once adequate sedation is achieved, the bronchoscope will be introduced through the mouth
beyond the vocal chords to the main carina and slowly advanced to the airway anastomosis.
Coughing that occurs with advancement of the bronchoscope from the chords to the anastomosis
will be addressed by maintaining the bronchoscope in an immobile neutral position for 60-180
seconds until coughing stops and the cough provocation will be performed.
Cough provocation Airway irritants will be applied in the following sequence: 1) one cm
distal to anastomosis, 2) one cm proximal to anastomosis and 3) at the main carina. Chemical
irritation will consist of 3 mL aliquots of 5 % dextrose water (D5W) instilled through the
bronchoscope channel on the bronchial mucosa (21). Aliquots of D5W will be administered at
each site on three separate occasions with a 60 second interval between administrations.
Mechanical irritation will involve placement of the biopsy foreceps on the bronchial mucosa
at each site. The sequence of airway irritation sites will always begin with the distal
anastomosis followed by the proximal anastomosis and main carina.
Airway lidocaine administration Patients demonstrating a cough reflex at the distal
anastomotic site will be recorded. After measurements are obtained at all airway sites, the
bronchoscope will be reintroduced to the distal anastomosis and 3 mL of 4 % lidocaine
instilled on the bronchial mucosa. Sixty seconds later, mechanical and chemical irritation of
the proximal and distal anastomosis will be performed as previously outlined.
Cough assessment Cough frequency will be determined by counting audible coughs and abdominal
muscle contractions measured with a surface electromyograph (EMG) recorder. Surface
electrodes placed on the skin, 2 cm below each costal margin along the midclavicular line
will be connected to an EMG recorder (Biopac Systems Inc, Santa Barbara, CA) linked to a
dedicated computer. Continuous EMG recordings will be obtained 15 seconds before
administration of the airway irritant to ensure absence of cough before airway irritant
administration (Figure 1). Twenty seconds or more of recording will be obtained after airway
irritant application. Cough will be defined as abdominal muscle contraction and audible
expiratory sound.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01469364 -
Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)
|
Phase 4 |